In the early days of the generative artificial intelligence boom, Sanofi’s chief digital officer, Emmanuel Frenehard, wasn’t particularly impressed with the AI tools that were being pitched.
The French pharmaceutical giant eschewed licensing an enterprise version of the AI chatbot ChatGPT for internal use. Frenehard also didn’t make Copilot, Microsoft’s AI assistant, widely available for employees after conducting a small pilot.
